ES8603271A1 - Un metodo de producir una composicion de interleuquina-2 - Google Patents

Un metodo de producir una composicion de interleuquina-2

Info

Publication number
ES8603271A1
ES8603271A1 ES542028A ES542028A ES8603271A1 ES 8603271 A1 ES8603271 A1 ES 8603271A1 ES 542028 A ES542028 A ES 542028A ES 542028 A ES542028 A ES 542028A ES 8603271 A1 ES8603271 A1 ES 8603271A1
Authority
ES
Spain
Prior art keywords
interleukin
stable composition
composition
present
lyophilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES542028A
Other languages
English (en)
Other versions
ES542028A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59071568A external-priority patent/JPS60215631A/ja
Priority claimed from JP60013226A external-priority patent/JPS60222424A/ja
Priority claimed from JP60037184A external-priority patent/JPS61197527A/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ES542028A0 publication Critical patent/ES542028A0/es
Publication of ES8603271A1 publication Critical patent/ES8603271A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

METODO DE PRODUCIR UNA COMPOSICION DE INTERLEUQUINA-2. CONSISTENTE EN INCORPORAR A UNA SOLUCION DE INTERLEUQUINA-2 HUMANA, RECOMBINANTE Y NO GLICOSILADA, EN CONCENTRACION DE 1 A 80.000 UNIDADES/ML DE AGUA Y CON UNA ACTIVIDAD ESPECIFICA DE 20.000 A 80.000 UNIDADES/MG, ALBUMINA DE SUERO HUMANO EN FORMA DE SOLUCION ACUOSA DE CONCENTRACION 0,1 A 50 MG/ML Y UN COMPUESTO REDUCTOR DE CARACTER ACIDO SELECCIONADO ENTRE GLUTATION, ACIDO TIOCTICO, ACIDO TIOALCANOICO DE 1 A 7 ATOMOS DE CARBONO Y OTROS, EN FORMA DE SOLUCION ACUOSA DE CONCENTRACION 0,05 A 20 MG/ML, HASTA AJUSTAR EL PH ENTRE 3 Y 6. ESTA COMPOSICION ASI PREPARADA PUEDE DEJARSE EN FORMA DE SOLUCION ACUOSA, CONGELARSE O LIOFILIZARSE. SE UTILIZA COMO UN NUEVO TIPO DE AGENTE ANTICANCER O COMO AGENTE TERAPEUTICO PARA INMUNODEFICIENCIA.
ES542028A 1984-04-09 1985-04-08 Un metodo de producir una composicion de interleuquina-2 Expired ES8603271A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59071568A JPS60215631A (ja) 1984-04-09 1984-04-09 インタ−ロイキン−２組成物
JP60013226A JPS60222424A (ja) 1985-01-25 1985-01-25 インタ−ロイキン−２組成物
JP60037184A JPS61197527A (ja) 1985-02-25 1985-02-25 インタ−ロイキン−２組成物

Publications (2)

Publication Number Publication Date
ES542028A0 ES542028A0 (es) 1985-12-16
ES8603271A1 true ES8603271A1 (es) 1985-12-16

Family

ID=27280163

Family Applications (1)

Application Number Title Priority Date Filing Date
ES542028A Expired ES8603271A1 (es) 1984-04-09 1985-04-08 Un metodo de producir una composicion de interleuquina-2

Country Status (13)

Country Link
US (2) US4645830A (es)
EP (1) EP0158487B1 (es)
KR (1) KR920005048B1 (es)
AU (1) AU579359B2 (es)
CA (1) CA1285478C (es)
DE (1) DE3583880D1 (es)
DK (1) DK148885A (es)
ES (1) ES8603271A1 (es)
IE (1) IE58161B1 (es)
IL (1) IL74823A (es)
NZ (1) NZ211702A (es)
PH (1) PH22897A (es)
PT (1) PT80247B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US5702699A (en) * 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
AU598300B2 (en) * 1986-09-04 1990-06-21 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
FR2639232A1 (fr) * 1988-10-21 1990-05-25 Sanofi Sa Medicaments contenant une interleukine-2 glycosylee
US5417970A (en) * 1988-10-21 1995-05-23 Sanofi Drugs containing a glycosylated interleukin-2
KR910700061A (ko) * 1988-12-06 1991-03-13 오스카 아끼히꼬 인터로이킨-1β의 안정화 조성물
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5164486A (en) * 1989-01-09 1992-11-17 Meiji Milk Products Co., Ltd. Method of inhibiting large cell formation
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
CA1339070C (en) * 1989-01-26 1997-07-29 Wulf Droge Treatment of diseases associated with cysteine deficiency
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
IT1240314B (it) * 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
ATE159260T1 (de) * 1990-11-23 1997-11-15 Roussel Uclaf Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins
DE59109176D1 (de) * 1991-03-19 2000-02-17 Huntsman International Trading Verfahren zur Herstellung von geschäumten Massen auf Basis von Polyharnstoffelastomeren
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
WO1995002411A1 (en) * 1993-07-16 1995-01-26 Mallinckrodt Veterinary Limited Stabilised polypeptide growth factor formulation at low ph
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US7135458B1 (en) 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
CA2389429C (en) 1999-11-18 2012-05-29 Victor E. Shashoua Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
CA2447292A1 (en) * 2001-05-17 2002-11-21 Ceremedix, Inc. Peptide compounds for counteracting reactive oxygen species and free radicals
DE10159245A1 (de) * 2001-12-03 2003-06-18 Degussa Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
ATE489950T1 (de) * 2006-06-22 2010-12-15 Gambro Lundia Ab Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung
CN102869679B (zh) 2010-04-27 2015-11-25 Scil技术股份有限公司 稳定的水性mia/cd-rap制剂
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
US11173208B2 (en) 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
EP3938742A1 (en) 2019-03-14 2022-01-19 Terumo BCT Biotechnologies, LLC Multi-part lyophilization container and method of use
IL294388A (en) 2020-01-14 2022-08-01 Synthekine Inc il2 orthologs and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4404280A (en) * 1981-07-16 1983-09-13 Steven Gillis Process for preparing murine interleukin 2 in the presence of interleukin 1 from an interleukin 2 nonproducer malignant cell line and cell line therefor
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins

Also Published As

Publication number Publication date
EP0158487A2 (en) 1985-10-16
PH22897A (en) 1989-01-19
IL74823A0 (en) 1985-07-31
KR920005048B1 (ko) 1992-06-26
AU579359B2 (en) 1988-11-24
DK148885D0 (da) 1985-04-02
NZ211702A (en) 1988-11-29
KR850007378A (ko) 1985-12-04
AU4083985A (en) 1985-10-17
DK148885A (da) 1985-10-10
EP0158487A3 (en) 1987-08-19
PT80247B (pt) 1987-10-20
EP0158487B1 (en) 1991-08-28
PT80247A (en) 1985-05-01
IL74823A (en) 1989-07-31
ES542028A0 (es) 1985-12-16
US4645830A (en) 1987-02-24
IE850902L (en) 1985-10-09
IE58161B1 (en) 1993-07-28
DE3583880D1 (de) 1991-10-02
CA1285478C (en) 1991-07-02
US4812557A (en) 1989-03-14

Similar Documents

Publication Publication Date Title
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
ES8900017A1 (es) Procedimiento para la preparacion de dipeptidos de n,n-dialquil-guanidino.
GR3006499T3 (es)
GR3005040T3 (es)
DK168790D0 (es)
GR3007385T3 (es)
GR3006807T3 (es)
DE3065473D1 (en) Method of stabilizing interferon and composition containing it
IT1207504B (it) Composizione moderatrice dell'appetito ed antigastrica.
ES8609728A1 (es) Una composicion de conjugado de enzima estabilizado
DE3480258D1 (en) Injectable therapeutic compositions containing stable s-adenosyl-l-methionine salts
AU585279B2 (en) Pesticidal biphenylyloxy and biphenylylalkoxy aryl acyl urea compounds
HU912742D0 (en) T-pa pro-stabilization
NZ219284A (en) Fluoboric acid salt of n-tridecyl-2,6-dimethylmorpholine and pesticidal compositions
ES8800139A2 (es) Mejoras introducidas en el objeto de la patente principal por un procedimiento para la preparacion de derivados de urea.
CA1264325C (en) AROYLIMIDAZOLONES
ES2001042A6 (es) Un metodo para la preparacion de acidos 5,6-dialcoxiantranilicos
SU1167881A1 (ru) Фенилгидразид морфолинодиэтилуксусной кислоты, обладающий противотуберкулезным действием
GR3005553T3 (es)
AU92306S (en) Buddha figurine
HUT37338A (en) Method for producing meat fluor securing the optimum function of alimentary canal
JO1352B1 (en) Quickly absorbable formulation from low soluble effective agents
SU1198912A1 (ru) Арилгидразиды 2-бутилгекс-2-еновой кислоты, проявляющие противотуберкулезную активность, и способ их получения
SU1233456A1 (ru) Способ получения замещенных n-[(1,3,5-триазин-2-ил)аминокарбонил]бензолсульфонамидов

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971001